Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2025 | $4.00 | Equal Weight | Wells Fargo |
| 9/10/2024 | $20.00 | Buy | Goldman |
| 9/10/2024 | Outperform → Perform | Oppenheimer | |
| 9/10/2024 | $10.60 → $16.00 | Hold → Buy | Jefferies |
| 5/10/2024 | $15.00 | Equal Weight → Overweight | Barclays |
| 4/20/2023 | $12.50 | Underperform → Hold | Jefferies |
| 4/19/2023 | $29.00 | Outperform → Strong Buy | Raymond James |
| 4/13/2023 | $29.00 | Outperform | Raymond James |
Wells Fargo initiated coverage of Relay Therapeutics with a rating of Equal Weight and set a new price target of $4.00
Goldman resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $20.00
Oppenheimer downgraded Relay Therapeutics from Outperform to Perform
8-K - Relay Therapeutics, Inc. (0001812364) (Filer)
8-K - Relay Therapeutics, Inc. (0001812364) (Filer)
8-K - Relay Therapeutics, Inc. (0001812364) (Filer)